Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?

Publisher： Karger

E-ISSN： 2296-5262|34|10|559-560

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.10, 2011-09, pp. : 559-560

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

By  

Oncology Research and Treatment, Vol. 33, Iss. 5, 2010-04 ,pp. : 231-238

Karger

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression

By  

Oncology Research and Treatment, Vol. 39, Iss. 10, 2016-09 ,pp. : 605-614

Karger

Access to resources Recommend Favorite

Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung Cancer

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 234-242

Karger

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite